FR3806M - Médicament a base d'un dérivé de la quinazolone-(4). - Google Patents

Médicament a base d'un dérivé de la quinazolone-(4).

Info

Publication number
FR3806M
FR3806M FR985329A FR985329A FR3806M FR 3806 M FR3806 M FR 3806M FR 985329 A FR985329 A FR 985329A FR 985329 A FR985329 A FR 985329A FR 3806 M FR3806 M FR 3806M
Authority
FR
France
Prior art keywords
quinazolone
derivative
product based
medicinal product
medicinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR985329A
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Farbwerke Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG, Farbwerke Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of FR3806M publication Critical patent/FR3806M/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR985329A 1963-05-18 1964-08-17 Médicament a base d'un dérivé de la quinazolone-(4). Active FR3806M (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEF39784A DE1231705B (de) 1963-05-18 1963-05-18 Verfahren zur Herstellung von 2, 3-substituierten Chinazolon-(4)-derivaten
DEF0042147 1964-02-28

Publications (1)

Publication Number Publication Date
FR3806M true FR3806M (fr) 1966-01-03

Family

ID=25975761

Family Applications (1)

Application Number Title Priority Date Filing Date
FR985329A Active FR3806M (fr) 1963-05-18 1964-08-17 Médicament a base d'un dérivé de la quinazolone-(4).

Country Status (10)

Country Link
US (1) US3322756A (US20040242566A1-20041202-C00022.png)
AT (3) AT258918B (US20040242566A1-20041202-C00022.png)
BE (1) BE648093A (US20040242566A1-20041202-C00022.png)
CH (3) CH447183A (US20040242566A1-20041202-C00022.png)
DE (2) DE1231705B (US20040242566A1-20041202-C00022.png)
DK (3) DK104409C (US20040242566A1-20041202-C00022.png)
FR (1) FR3806M (US20040242566A1-20041202-C00022.png)
GB (1) GB1053063A (US20040242566A1-20041202-C00022.png)
NL (1) NL6405448A (US20040242566A1-20041202-C00022.png)
SE (3) SE314074B (US20040242566A1-20041202-C00022.png)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010221A1 (en) * 1995-09-15 1997-03-20 Torrey Pines Institute For Molecular Studies Synthesis of quinazolinone libraries

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1003802A (en) * 1963-06-04 1965-09-08 Searle & Co Pyrimidinone derivatives
GB1062357A (en) * 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
DE2027645A1 (de) * 1970-06-05 1971-12-09 Byk Gulden Lomberg Chemische Fa bnk GmbH, 7750 Konstanz Piperazinylalkyl chinazolon (4) den vate, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel
US3900476A (en) * 1973-05-17 1975-08-19 Upjohn Co 2(2'-pyrimidylamino)quinazolines and their preparation
US3936453A (en) * 1974-01-28 1976-02-03 Sandoz, Inc. 1-Substituted-2-disubstituted aminoquin azolin-4(1h)-ones
US3959279A (en) * 1974-01-28 1976-05-25 Sandoz, Inc. 1-Substituted-2-imino-quinazolin-4(1H)ones
US4113637A (en) * 1974-09-10 1978-09-12 Institut Francais Du Petrole Alkyl-guanidino-heterocyclic compounds, their manufacture and use as additives for fuels and lubricants
GB8429739D0 (en) * 1984-11-24 1985-01-03 Fbc Ltd Fungicides
US5756502A (en) * 1994-08-08 1998-05-26 Warner-Lambert Company Quinazolinone derivatives as cholyecystokinin (CCK) ligands
US6258819B1 (en) * 1999-08-05 2001-07-10 Syntex (U.S.A.) Llc Substituted 2(4-piperidyl)-4(3H)-quinazolinones and 2-(4-piperidyl)-4(3H)-azaquinazolinones
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US7671200B2 (en) * 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
SI2223922T1 (sl) * 2000-04-25 2016-04-29 Icos Corporation Inhibitorji humane fosfatidil-inositol 3-kinazne delta izoforme
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
WO2002094790A1 (fr) * 2001-05-23 2002-11-28 Mitsubishi Pharma Corporation Compose heterocyclique condense et son utilisation medicale
CA2465491A1 (en) * 2001-11-07 2003-05-15 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2003043995A1 (en) * 2001-11-20 2003-05-30 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
JP2005529076A (ja) * 2002-02-15 2005-09-29 サイトキネティクス・インコーポレーテッド キナゾリノンの合成
MXPA04011074A (es) * 2002-05-09 2005-06-08 Cytokinetics Inc Compuestos de pirimidinona, composiciones y metodos.
AU2003270015A1 (en) 2002-05-09 2003-12-02 Cytokinetics, Inc. Compounds, compositions, and methods
EP1513820A4 (en) * 2002-05-23 2006-09-13 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
AU2003236527A1 (en) * 2002-06-14 2003-12-31 Cytokinetics, Inc. Compounds, compositions, and methods
US7211580B2 (en) * 2002-07-23 2007-05-01 Cytokinetics, Incorporated Compounds, compositions, and methods
JP2005536553A (ja) * 2002-08-21 2005-12-02 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
WO2004034972A2 (en) * 2002-09-30 2004-04-29 Cytokinetics, Inc. Compounds, compositions, and methods
US7550590B2 (en) 2003-03-25 2009-06-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
ZA200602051B (en) 2003-08-13 2007-10-31 Takeda Pharmaceutical 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
WO2005016348A1 (en) * 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
US20050054614A1 (en) * 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
WO2005026148A1 (en) * 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
JP2007513058A (ja) * 2003-09-08 2007-05-24 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
US20050197327A1 (en) * 2003-11-03 2005-09-08 Gustave Bergnes Compounds, compositions, and methods
US20050148593A1 (en) * 2003-11-07 2005-07-07 Gustave Bergnes Compounds, compositions, and methods
US7439254B2 (en) * 2003-12-08 2008-10-21 Cytokinetics, Inc. Compounds, compositions, and methods
CN102127053A (zh) * 2004-03-15 2011-07-20 武田药品工业株式会社 二肽基肽酶抑制剂
HUE030950T2 (en) 2004-05-13 2017-06-28 Icos Corp Quinazolinones as 3-kinase delta inhibitors of human phosphatidylinositol
CA2567883A1 (en) * 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
US7872124B2 (en) 2004-12-21 2011-01-18 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2006089106A2 (en) * 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
DE102005024017A1 (de) * 2005-05-25 2006-11-30 Merck Patent Gmbh Chinazolinone
WO2007033265A1 (en) * 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetis
DK1942898T4 (da) 2005-09-14 2014-06-02 Takeda Pharmaceutical Dipeptidylpeptidase-inhibitorer til behandling af diabetes
KR101368988B1 (ko) * 2005-09-16 2014-02-28 다케다 야쿠힌 고교 가부시키가이샤 디펩티딜 펩티다제 억제제
JP2009531456A (ja) * 2006-03-28 2009-09-03 武田薬品工業株式会社 （ｒ）−３−アミノピペリジン二塩酸塩の調製
EP2233472B1 (en) * 2006-03-28 2014-01-15 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
PE20081150A1 (es) * 2006-09-13 2008-10-03 Takeda Pharmaceutical Inhibidores de dipetidilpeptidasa
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) * 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CA3092449A1 (en) 2008-11-13 2010-05-20 Gilead Calistoga Llc Therapies for hematologic malignancies
EP2411391A1 (en) 2009-03-24 2012-02-01 Gilead Calistoga LLC Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
ES2548253T3 (es) * 2009-04-20 2015-10-15 Gilead Calistoga Llc Métodos para el tratamiento de tumores sólidos
MX2012000817A (es) 2009-07-21 2012-05-08 Gilead Calistoga Llc Tratamiento para desordenes del higado con inhibidores pi3k.
US9353067B2 (en) 2011-04-10 2016-05-31 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
PE20141792A1 (es) 2012-03-05 2014-12-07 Gilead Calistoga Llc Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluor-3-fenilquinazolin-4(3h)-ona
EP3083623A1 (en) 2013-12-20 2016-10-26 Gilead Calistoga LLC Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
CA2934531C (en) 2013-12-20 2020-02-25 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
CN106459005A (zh) 2014-06-13 2017-02-22 吉利德科学公司 磷脂酰肌醇3‑激酶抑制剂

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010221A1 (en) * 1995-09-15 1997-03-20 Torrey Pines Institute For Molecular Studies Synthesis of quinazolinone libraries

Also Published As

Publication number Publication date
SE314075B (US20040242566A1-20041202-C00022.png) 1969-09-01
AT258917B (de) 1967-12-27
CH447182A (de) 1967-11-30
GB1053063A (US20040242566A1-20041202-C00022.png)
DK104409C (da) 1966-05-16
DK105765C (da) 1966-11-07
NL6405448A (US20040242566A1-20041202-C00022.png) 1964-11-19
DE1231705B (de) 1967-01-05
AT258918B (de) 1967-12-27
DE1249281B (US20040242566A1-20041202-C00022.png)
BE648093A (US20040242566A1-20041202-C00022.png) 1964-11-19
CH447183A (de) 1967-11-30
SE314074B (US20040242566A1-20041202-C00022.png) 1969-09-01
AT254193B (de) 1967-05-10
DK106039C (da) 1966-12-12
SE314076B (US20040242566A1-20041202-C00022.png) 1969-09-01
US3322756A (en) 1967-05-30
CH447181A (de) 1967-11-30

Similar Documents

Publication Publication Date Title
FR3806M (fr) Médicament a base d'un dérivé de la quinazolone-(4).
FR1837M (fr) Médicament a base d'un dérivé méthylolé de la β-carboline.
FR3769M (fr) Médicament a base de dérivés d'imidazolidone.
FR3540M (fr) Médicament a base de dérivés de la 7-hydroxy-2-oxo-1.2-dihydroquinoléine.
FR2186M (fr) Médicament a base d'un dérivé de l'aniline.
FR3348M (fr) Médicament a base d'un nouveau dérivé de la 5.6-dihydromorphanthridine.
FR3405M (fr) Médicament a base d'une sulfométhyl-polymyxine.
FR2094M (fr) Médicament a base d'un nouvel hendécapeptide.
FR3148M (fr) Médicament a base d'un nouveau dérivé de la 5.6-dihydromorphanthridine.
FR1891M (fr) Médicament a base d'un phénoxy-alcane.
FR3202M (fr) Médicament a base de dérivé de théophylline.
FR2869M (fr) Médicament a base d'un dérivé de la cymarine.
FR3724M (fr) Médicament a base d'anisoyl-3 hydroxy-4 p. méthoxy-phényl-6α-pyrone.
FR3766M (fr) Médicament a base de dérivés de naphtamidines.
FR3323M (fr) Médicament a base de dérivé de l'aza-thiaxanthene.
FR3045M (fr) Médicament a base d'un nouveau dérivé de la phénothiazine.
FR3351M (fr) Médicament a base d'un nouveau dérivé de la 1.2-diphényl-3.5-dioxo-pyrazolidine.
FR3144M (fr) Médicament a base d'un dérivé de cyclopentyl-benzylamine.
FR3649M (fr) Médicament a base d'un nouveau dérivé de l'indole.
FR3788M (fr) Médicament a base de thiosemicarbazones d'aldéhydes insaturés.
FR3778M (fr) Médicament a base d'un nouveau dérivé de thiophene.
FR2093M (fr) Médicament a base de dérivé d'hydroxy-dibenzocycloheptane.
FR2877M (fr) Médicament a base d'amides.
FR3798M (fr) Médicament a base d'un nouveau dérivé de l'anthracene.
FR3565M (fr) Médicament a base d'un nonapeptide-amide cyclique.